Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?

Zilli, Thomas; Schick, Ulrike; Ozsahin, Mahmut; Gervaz, Pascal; Roth, Arnaud; Allal, Abdelkarim Said

doi:10.1016/j.radonc.2011.09.015

Scientific article

English

Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?

ContributorsZilli, Thomas; Schick, Ulrike; Ozsahin, Mahmut; Gervaz, Pascal; Roth, Arnaud; Allal, Abdelkarim Said

Published inRadiotherapy and oncology, vol. 102, no. 1, p. 62-67

Publication date2012

Abstract

To evaluate the influence of concomitant chemotherapy on loco-regional control (LRC) and cancer-specific survival (CSS) in patients with T1-T2 N0 M0 anal cancer treated conservatively by primary radiotherapy (RT).

Keywords

Aged
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Anus Neoplasms/pathology/therapy
Chemoradiotherapy/methods
Combined Modality Therapy
Female
Fluorouracil/administration & dosage
Humans
Male
Middle Aged
Mitomycin/administration & dosage
Neoplasm Staging
Survival Rate
Treatment Outcome

Affiliation entities

Research groups

Citation (ISO format)

ZILLI, Thomas et al. Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy? In: Radiotherapy and oncology, 2012, vol. 102, n° 1, p. 62–67. doi: 10.1016/j.radonc.2011.09.015

Article (Published version)

Identifiers

PID : unige:28753
DOI : 10.1016/j.radonc.2011.09.015
PMID : 21993403

Journal ISSN0167-8140

800views

0downloads

Creation03/06/2013 13:14:00

First validation03/06/2013 13:14:00

Update time14/03/2023 20:19:37

Status update14/03/2023 20:19:36

Last indexation30/10/2024 09:44:01

Archive ouverte UNIGE

Node-negative T1-T2 anal cancer: radiotherapy alone or concomitant chemoradiotherapy?

To evaluate the influence of concomitant chemotherapy on loco-regional control (LRC) and cancer-specific survival (CSS) in patients with T1-T2 N0 M0 anal cancer treated conservatively by primary radiotherapy (RT).

Technical informations